HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York. Show more
Location: 350 Fifth Avenue, New York, NY, 10118, United States | Website: https://www.hookipapharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
14.51M
52 Wk Range
$0.72 - $6.69
Previous Close
$1.23
Open
$1.21
Volume
47,341
Day Range
$1.15 - $1.24
Enterprise Value
-23.77M
Cash
40.28M
Avg Qtr Burn
-13.19M
Insider Ownership
19.29%
Institutional Own.
34.18%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Eseba-vec (HB-200) + pembrolizumab Details Cancer, Human papillomavirus, HPV+ oropharyngeal cancer | Phase 2/3 Update | |
HB-400 Details Hepatitis B | Phase 2 Data readout | |
Eseba-vec (HB-200) Details Cancer, Human papillomavirus, Head and neck squamous cell carcinomas | Phase 2 Data readout | |
HB-500 Details Human immunodeficiency virus | Phase 1b Data readout | |
HB-700 Details Cancer, Lung cancer, Colorectal cancer , Pancreatic cancer | Phase 1 Update | |
HB-300 Details Cancer, Castration-resistant prostate cancer | Failed Discontinued | |
HB-101 (VaxWave®) Details Cytomegalovirus, Infectious disease, Kidney transplantation | Failed Discontinued |